A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Subjects with Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Sponsors Sun Pharma Global FZE
- 23 Oct 2018 Planned End Date changed from 15 Apr 2020 to 31 Dec 2020.
- 23 Oct 2018 Planned primary completion date changed from 6 Dec 2019 to 6 Dec 2020.
- 16 Feb 2018 Planned End Date changed from 1 Sep 2019 to 15 Apr 2020.